Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 445Carcinoma, Non-Small-Cell Lung 224Breast Neoplasms 189Ovarian Neoplasms 167Glioblastoma 156Neoplasms 126Carcinoma, Hepatocellular 124Rectal Neoplasms 112Colonic Neoplasms 107Neoplasm Metastasis 104Brain Neoplasms 96Lung Neoplasms 91Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 71Glioma 69Pancreatic Neoplasms 54Gliosarcoma 43Melanoma 42Liver Neoplasms 42Uterine Cervical Neoplasms 40Stomach Neoplasms 37Adenocarcinoma of Lung 36Recurrence 33Astrocytoma 30Endometrial Neoplasms 27Carcinoma, Ovarian Epithelial 27Triple Negative Breast Neoplasms 26Prostatic Neoplasms 22Kidney Neoplasms 22Esophageal Neoplasms 21

Interventions

belzutifan 4gallium Ga 68 dotatate 3Everolimus 2vatalanib 1tanespimycin 1spartalizumab 1palbociclib 1lenvatinib 1cabozantinib 1Vorinostat 1Sunitinib 1Ranibizumab 1Propranolol 1PT2385 1Oxygen-15 1Nivolumab 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × von Hippel-Lindau Disease × Bevacizumab × Clear all
NCT01015300 2012-05-11

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Dartmouth-Hitchcock Medical Center

Phase EARLY_PHASE1 Terminated
1 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡